EV Nickel Inc. | WebDisclosure

Basculer en Français

9480	Companies
185535	Keywords
117927	Articles
99378	Press releases

Home
Companies
EV Nickel Inc.

PRESS RELEASE

published on 09/04/2024 at 13:00, 1 year 3 months ago

EV Nickel Confirms High-Grade Nickel at Langmuir #2 Intersecting Nickel Grades from 1.07% to 5.11%
EV Nickel Inc. reports high-grade nickel intercepts including 5.11% Ni in Langmuir #2 Nickel Zone, with assay results indicating high nickel tenor. Company plans further drilling to advance Canadian nickel supply chain

Drilling Program Assay Results EV Nickel Inc. High-grade Nickel Canadian Nickel Supply Chain
BRIEF

published on 08/16/2024 at 10:46, 1 year 3 months ago

First Berlin Equity Research Reaffirms BUY Rating for APONTIS PHARMA AG

First Berlin Equity Research Buy Recommendation APONTIS PHARMA AG H1/24 Results Single Pill Business
BRIEF

published on 08/16/2024 at 10:46, 1 year 3 months ago

First Berlin Equity Research réaffirme la note d'ACHAT pour APONTIS PHARMA AG

APONTIS PHARMA AG Recommandation D'achat Première Recherche Sur Les Actions À Berlin Résultats H1/24 Entreprise De Pilules Individuelles
PRESS RELEASE

published on 08/16/2024 at 10:41, 1 year 3 months ago

Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research recommends buying APONTIS PHARMA AG shares with a target price of €17 after solid H1/24 results and positive outlook. Analyst Christian Orquera maintains his BUY rating

First Berlin Equity Research Buy Recommendation APONTIS PHARMA AG H1/24 Results Christian Orquera
PRESS RELEASE

published on 08/12/2024 at 18:16, 1 year 3 months ago

Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
Montega AG stuft APONTIS PHARMA AG mit Kaufempfehlung und Kursziel von 16,50 EUR. APONTIS PHARMA zeigt solide Q2-Entwicklung und ermutigende Erfolge in neuer Vertriebsstrategie

Montega AG Kaufempfehlung APONTIS PHARMA AG Kursziel 16,50 EUR Solide Entwicklung
BRIEF

published on 08/09/2024 at 07:35, 1 year 3 months ago

APONTIS PHARMA Reports Strong Half-Year Growth in 2024

Revenue Growth APONTIS PHARMA Single Pill Combinations EBITDA Improvement Novartis Cooperation
BRIEF

published on 08/09/2024 at 07:35, 1 year 3 months ago

APONTIS PHARMA annonce une forte croissance au premier semestre 2024

APONTIS PHARMA Croissance Des Revenus Amélioration De L'EBITDA Combinaisons De Pilules Simples Coopération Avec Novartis
PRESS RELEASE

published on 08/09/2024 at 07:30, 1 year 3 months ago

APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
APONTIS PHARMA reports profitable revenue growth with Single Pill combinations in the first half of 2024. Forecast for full year 2024 confirmed. Earnings and sales improvements noted

EBITDA Revenue Growth Forecast APONTIS PHARMA Single Pill Combinations
BRIEF

published on 06/27/2024 at 07:35, 1 year 5 months ago

APONTIS PHARMA AG Appoints CFO Thomas Zimmermann to Management Board

Management Board APONTIS PHARMA ESG Strategy Thomas Zimmermann Single Pill
BRIEF

published on 06/27/2024 at 07:35, 1 year 5 months ago

APONTIS PHARMA AG nomme le directeur financier Thomas Zimmermann au conseil d'administration

Conseil D'administration Stratégie ESG PHARMA APONTIS Thomas Zimmermann Pilule Unique

Accesswire

Published on 12/05/2025 at 19:50, 23 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 53 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 28 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 53 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 2 hours 13 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 15 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 1 hour 47 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 1 hour 58 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours 22 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 27 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours 55 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 55 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 3 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 3 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 15 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE